6-fluoro-5-piperazin-1-yl-3-(1H-pyrrol-2-yl)-1H-benzo[cd]indol-2-one acetic acid salt | 444099-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-fluoro-5-piperazin-1-yl-3-(1H-pyrrol-2-yl)-1H-benzo[cd]indol-2-one acetic acid salt
• 英文别名: acetic acid;6-fluoro-5-piperazin-1-yl-3-(1H-pyrrol-2-yl)-1H-benzo[cd]indol-2-one
• CAS: 444099-88-1
• 化学式: C₂H₄O₂*C₁₉H₁₇FN₄O
• 分子量: 396.421
• InChiKey: UZWCMFALYCSKHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  97.5
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Naphthostyrils
  申请人：——

  公开号：US20020147343A1

  公开（公告）日：2002-10-10

  Disclosed are novel naphthostyrils of formula 1 These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing such compounds, methods for the treatment and/or prevention of cancer using such compositions, and intermediates useful in the preparation of the compounds of formula I.

  本发明涉及一种新型萘基苯基丙酮类化合物，其化学式为1。这些化合物抑制细胞周期依赖性激酶（CDKs），尤其是CDK2。这些化合物及其药学上可接受的盐和酯是抗增殖剂，可用于治疗或控制细胞增殖性疾病，尤其是癌症。本发明还涉及含有这些化合物的制药组合物，使用这些组合物治疗和/或预防癌症的方法，以及制备式I化合物的中间体。
• NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1358180A2

  公开（公告）日：2003-11-05
• US6504034B2
  申请人：——

  公开号：US6504034B2

  公开（公告）日：2003-01-07
• US6531598B1
  申请人：——

  公开号：US6531598B1

  公开（公告）日：2003-03-11
• [EN] NAPHTHOSTYRILS<br/>[FR] NAPHTOSTYRILES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002059109A2

  公开（公告）日：2002-08-01

  Disclosed are novel naphthostyrils of formula I. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing such compounds, methods for the treatment and/or prevention of cancer using such composition, and intermediates useful in the preparation of the compounds of formula I.